Zhejiang University is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Zhejiang University (ZJU) is one of China's top national universities and a leading research institution in Asia. Founded in 1897, it has grown to become one of China's most prestigious universities with strong programs in medicine, life sciences, and neuroscience. The university is at the forefront of neurodegenerative disease research in China. [1]
| Attribute | Details |
|---|---|
| Location | Hangzhou, Zhejiang Province, China |
| Type | Public Research University |
| Founded | 1897 |
| Students | ~60,000 |
| Website | zju.edu.cn |
| Medical School | Zhejiang University School of Medicine |
| Affiliated Hospitals | 7 affiliated hospitals |
Zhejiang University was founded in 1897 as Qiushi Academy (求是书院), making it one of China's oldest modern universities. The institution evolved through multiple transformations, including the merger of several specialized colleges in 1952 and subsequent expansions. The School of Medicine traces its roots to Zhejiang Provincial Medical School, established in 1912[1:1].
In the 1990s and 2000s, Zhejiang University underwent significant expansion, merging with the University of Hangzhou and other institutions to become one of China's largest and most comprehensive universities. The university's "World-Class University" initiative has propelled it into the top 100 globally, with particular strength in life sciences and medicine.
Zhejiang University's School of Medicine conducts extensive research on neurodegenerative diseases through multiple institutes and centers[1:2].
Institute of Neurology
The Institute focuses on:
Brain Research Institute
A dedicated institute for neuroscience research:
Research areas include:
Research programs focus on:
The Alzheimer's disease research program at Zhejiang University encompasses:
Genetic Studies:
Biomarker Development:
Clinical Trials:
The Parkinson's disease research program focuses on:
Genetic Studies:
Clinical Research:
Therapeutic Development:
Zhejiang University has established a strong program in neuroinflammation:
Zhejiang University has established a unique program investigating traditional Chinese medicine (TCM) approaches to neurodegenerative diseases[17:1].
Herbal Medicine Studies:
Acupuncture Research:
| Compound | Source | Potential Application |
|---|---|---|
| Baicalein | Scutellaria baicalensis | Anti-inflammatory, neuroprotective |
| Curcumin | turmeric | Antioxidant, anti-amyloid |
| Ginsenosides | Panax ginseng | Cognitive enhancement |
| Huperzine A | Huperzia serrata | Acetylcholinesterase inhibitor |
Zhejiang University hosts several key research laboratories:
Each laboratory maintains specialized research programs:
State Key Laboratory of Cognitive Neuroscience
Zhejiang Provincial Key Laboratory
Zhejiang University has emerged as a leading center for neurodegeneration research in China:
A distinctive aspect of Zhejiang's research is the integration of traditional Chinese medicine:
Natural Product Screening
Mechanism Studies
The university maintains comprehensive clinical research capabilities:
Affiliated Hospitals
Clinical Trial Capabilities
The university provides excellent research training:
Zhejiang University participates in numerous clinical trials:
| Condition | Focus | Phase | Status |
|---|---|---|---|
| Alzheimer's disease | Anti-amyloid antibody | Phase 3 | Recruiting |
| Alzheimer's disease | Tau aggregation inhibitor | Phase 2 | Ongoing |
| Parkinson's disease | Gene therapy | Phase 1/2 | Enrolling |
| Alzheimer's disease | Traditional Chinese medicine | Phase 2 | Active |
| Vascular dementia | Prevention trial | Phase 3 | Recruiting |
Zhejiang University has emerged as a leading center for neurodegeneration research in China, contributing significantly to understanding neurodegenerative diseases in Asian populations. The institution's unique strengths include:
Genetic Epidemiology: Contributing to understanding of genetic risk factors specific to Chinese and Asian populations.
Traditional Chinese Medicine: Bridging traditional approaches with modern neuroscience to develop novel therapeutic strategies.
Clinical Research: Extensive clinical trial infrastructure enabling participation in international therapeutic development efforts.
International Collaboration: Strong partnerships with leading institutions worldwide, facilitating knowledge exchange and joint research.
The university's commitment to combining cutting-edge neuroscience research with its unique cultural heritage positions it as a critical contributor to the global effort against neurodegenerative diseases.
Zhejiang University School of Medicine Annual Report 2024. 2024. ↩︎ ↩︎ ↩︎
Song W, et al. Molecular mechanisms of Alzheimer's disease in Chinese populations. Neuroscience Bulletin. 2023. ↩︎ ↩︎
Liu J, et al. Tau pathology in Chinese Alzheimer's disease patients. Alzheimer's & Dementia. 2021. ↩︎
Wang Y, et al. Parkinson's disease epidemiology in China. Journal of Neurology. 2022. ↩︎ ↩︎
Yu R, et al. GBA mutations in Chinese Parkinson's disease patients. Movement Disorders. 2023. ↩︎ ↩︎
Wu M, et al. LRRK2 mutations in Chinese PD patients. Neurology. 2022. ↩︎ ↩︎
Tang M, et al. Vascular dementia in Chinese populations. Stroke. 2023. ↩︎
Chen X, et al. Neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2023. ↩︎ ↩︎
Guo R, et al. Genetic epidemiology of Alzheimer's disease in China. Nature Genetics. 2022. ↩︎
Lu W, et al. APOE genotyping in Chinese AD patients. Journal of Alzheimer's Disease. 2021. ↩︎
Gong L, et al. Biomarkers for Alzheimer's disease in Chinese populations. Aging and Disease. 2022. ↩︎
Yang J, et al. Neuroimaging biomarkers in Chinese MCI patients. Radiology. 2022. ↩︎
Feng Y, et al. Clinical trials for Alzheimer's disease in China. Alzheimer's Research & Therapy. 2020. ↩︎
Lin Q, et al. Deep brain stimulation in Chinese PD patients. Neuromodulation. 2020. ↩︎
He P, et al. Sleep disorders and cognitive decline. Sleep Medicine. 2021. ↩︎
Zhao H, et al. Stem cell therapy for Parkinson's disease. Stem Cell Research & Therapy. 2021. ↩︎
Xu K, et al. Traditional Chinese medicine approaches to neurodegeneration. Journal of Ethnopharmacology. 2019. ↩︎ ↩︎
Huang S, et al. Gut microbiome and Parkinson's disease. Gut Microbes. 2023. ↩︎